Detalhe da pesquisa
1.
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Oncologist
; 26(7): e1133-e1142, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33909934
2.
Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.
Breast J
; 25(5): 880-888, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31290203
3.
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
Breast Cancer Res Treat
; 170(3): 535-545, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29654415
4.
Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
J Med Econ
; 26(1): 357-365, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36797664
5.
Patient experiences with patient-reported outcome measures in metastatic breast cancer trials: qualitative interviews.
J Patient Rep Outcomes
; 6(1): 60, 2022 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657533
6.
Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil.
Rev Saude Publica
; 56: 100, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36515302
7.
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Clin Breast Cancer
; 22(4): 326-335, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35034858
8.
Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2- advanced breast cancer.
Ther Adv Med Oncol
; 14: 17588359221081203, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35251320
9.
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Pharmacoeconomics
; 39(9): 1045-1058, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34105083
10.
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
Pharmacoeconomics
; 39(7): 853-867, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34002341
11.
Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer.
Cancer Manag Res
; 13: 8179-8189, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34754238
12.
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).
Ther Adv Med Oncol
; 12: 1758835920943065, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32782490
13.
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Breast
; 54: 148-154, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33065342
14.
Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom.
J Health Econ Outcomes Res
; 6(2): 20-31, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-32685577
15.
Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2- advanced breast cancer.
Cancer Manag Res
; 10: 1319-1327, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29861642
16.
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
Breast Cancer (Dove Med Press)
; 10: 69-78, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29765247
17.
Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Curr Med Res Opin
; 34(9): 1645-1652, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29781326
18.
Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
Clin Ther
; 40(4): 628-639.e3, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29609880
19.
Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?
Cancer Manag Res
; 10: 1015-1025, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29765249
20.
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
PLoS One
; 12(6): e0175920, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28636648